FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Robert Sharkey

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Concepts & Ideas

Disorders

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Robert M Sharkey; Catharina M van Rij; Otto C Boerman; Thomas M Cardillo; Chien-Hsing Chang; Cathelijne Frielink; Habibe Karacay; William J McBride; Celeste Regino; Edmund A Rossi; David M Goldenberg
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
David M Goldenberg; Robert M Sharkey
Using antibodies to target cancer therapeutics.
Robert M Sharkey; Chien-Hsing Chang; William J McBride; Edmund A Rossi; David M Goldenberg
Pretargeting: taking an alternate route for localizing radionuclides.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Robert Sharkey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2012: Robert M Sharkey; Catharina M van Rij; Otto C Boerman; Thomas M Cardillo; Chien-Hsing Chang; Cathelijne Frielink; Habibe Karacay; William J McBride; Celeste Regino; Edmund A Rossi; David M Goldenberg
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(10):1625-32.
2012: David M Goldenberg; Robert M Sharkey
Using antibodies to target cancer therapeutics.
Expert opinion on biological therapy 2012;12(9):1173-90.
2012: Robert M Sharkey; Chien-Hsing Chang; William J McBride; Edmund A Rossi; David M Goldenberg
Pretargeting: taking an alternate route for localizing radionuclides.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(3):591-600.
2012: William J McBride; Robert M Sharkey; Christopher A D'Souza; David M Goldenberg
The radiolabeling of proteins by the [18F]AlF method.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2012;70(1):200-4.
2011: Habibe Karacay; Robert M Sharkey; William J McBride; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(4):555-9.
2010: David M Goldenberg; Robert M Sharkey
Radioactive antibodies: a historical review of selective targeting and treatment of cancer.
Hospital practice (1995) 2010;38(5):82-93.
2010: William J McBride; Christopher A D'Souza; Robert M Sharkey; Habibe Karacay; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.
Bioconjugate chemistry 2010;21(7):1331-40.
2010: Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Seminars in nuclear medicine 2010;40(3):190-203.
2010: Robert M Sharkey; Habibe Karacay; David M Goldenberg
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.
Cancer 2010;116(4 Suppl):1134-45.
2009: Habibe Karacay; Robert M Sharkey; David V Gold; Dan R Ragland; William J McBride; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(12):2008-16.
2009: Robert M Sharkey; Oliver W Press; David M Goldenberg
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.
Blood 2009;113(17):3891-5.
2009: M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.
Cancer biotherapy & radiopharmaceuticals 2009;24(2):185-93.
2009: Robert M Sharkey; Habibe Karacay; Christine R Johnson; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(3):444-53.
2008: Robert M Sharkey; David M Goldenberg
Use of antibodies and immunoconjugates for the therapy of more accessible cancers.
Advanced drug delivery reviews 2008;60(12):1407-20.
2008: Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Cancer research 2008;68(13):5282-90.
2008: David V Gold; David M Goldenberg; Habibe Karacay; Edmund A Rossi; Chien-Hsing Chang; Thomas M Cardillo; William J McBride; Robert M Sharkey
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Cancer research 2008;68(12):4819-26.
2008: Robert M Sharkey; Habibe Karacay; Shankar Vallabhajosula; William J McBride; Edmund A Rossi; Chien-Hsing Chang; Stanley J Goldsmith; David M Goldenberg
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
Radiology 2008;246(2):497-507.
2008: David M Goldenberg; Edmund A Rossi; Robert M Sharkey; William J McBride; Chien-Hsing Chang
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(1):158-63.
2007: Robert M Sharkey; Habibe Karacay; William J McBride; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5577s-5585s.
2007: Pierre-Yves Brard; Habibe Karacay; Rhona Stein; Robert M Sharkey; M Jules Mattes; Chien-Hsing Chang; Edmund A Rossi; William J McBride; David M Goldenberg
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5564s-5571s.
2007: David M Goldenberg; Robert M Sharkey
Novel radiolabeled antibody conjugates.
Oncogene 2007;26(25):3734-44.
2006: David M Goldenberg; Robert M Sharkey
Advances in cancer therapy with radiolabeled monoclonal antibodies.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2006;50(4):248-64.
2006: William J McBride; Pat Zanzonico; Robert M Sharkey; Carl Norén; Habibe Karacay; Edmund A Rossi; Michele J Losman; Pierre-Yves Brard; Chien-Hsing Chang; Steven M Larson; David M Goldenberg
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(10):1678-88.
2006: Dieter Moosmayer; Dietmar Berndorff; Chien-Hsing Chang; Robert M Sharkey; Axel Rother; Sandra Borkowski; Edmund A Rossi; William J McBride; Thomas M Cardillo; David M Goldenberg; Ludger M Dinkelborg
Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5587-95.
2006: Robert M Sharkey; David M Goldenberg
Targeted therapy of cancer: new prospects for antibodies and immunoconjugates.
CA: a cancer journal for clinicians 2006;56(4):226-43.
2006: Robert M Sharkey
Radioimmunotherapy against the tumor vasculature: A new target?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(7):1070-4.
2006: Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; William J McBride; Robert M Sharkey; Chien-Hsing Chang
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(18):6841-6.
2006: Jean-François Chatal; Loïc Campion; Françoise Kraeber-Bodéré; Stéphane Bardet; Jean-Philippe Vuillez; Bernard Charbonnel; Vincent Rohmer; Chien-Hsing Chang; Robert M Sharkey; David M Goldenberg; Jacques Barbet
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1705-11.
2006: David M Goldenberg; Robert M Sharkey; Giovanni Paganelli; Jacques Barbet; Jean-François Chatal
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(5):823-34.
2006: Robert M Sharkey; David M Goldenberg
Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.
Cancer investigation 2006;24(1):82-97.
2006: David V Gold; David E Modrak; Zhiliang Ying; Thomas M Cardillo; Robert M Sharkey; David M Goldenberg
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(2):252-8.
2005: Habibe Karacay; Pierre-Yves Brard; Robert M Sharkey; Chien-Hsing Chang; Edmund A Rossi; William J McBride; Dan R Ragland; Ivan D Horak; David M Goldenberg
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7879-85.
2005: Robert M Sharkey; Thomas M Cardillo; Edmund A Rossi; Chien-Hsing Chang; Habibe Karacay; William J McBride; Hans J Hansen; Ivan D Horak; David M Goldenberg
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Nature medicine 2005;11(11):1250-5.
2005: Edmund A Rossi; Chien-Hsing Chang; Michele J Losman; Robert M Sharkey; Habibe Karacay; William McBride; Thomas M Cardillo; Hans J Hansen; Zhengxing Qu; Ivan D Horak; David M Goldenberg
Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7122s-7129s.
2005: Robert M Sharkey; Habibe Karacay; Thomas M Cardillo; Chien-Hsing Chang; William J McBride; Edmund A Rossi; Ivan D Horak; David M Goldenberg
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7109s-7121s.
2005: Jeffry A Siegel; Richard B Sparks; Robert M Sharkey; Barry W Wessels; Wesley E Bolch; Lionel Gerard Bouchet; Hazel Breitz; Ruby F Meredith; George Sgouros; Michael G Stabin
Blood-based red marrow dosimetry: where's the beef?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(8):1404-6; author reply 1405-6.
2005: Robert M Sharkey; Habibe Karacay; Chien-Hsing Chang; William J McBride; Ivan D Horak; David M Goldenberg
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Leukemia 2005;19(6):1064-9.
2005: Robert M Sharkey; Jack Burton; David M Goldenberg
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal.
Expert review of clinical immunology 2005;1(1):47-62.
2005: Robert M Sharkey; George Hajjar; Dion Yeldell; Arnold Brenner; Jack Burton; Arnold Rubin; David M Goldenberg
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(4):620-33.
2005: Robert M Sharkey
The direct route may not be the best way to home.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(3):391-4.
2005: Robert M Sharkey; David M Goldenberg
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46 Suppl 1():115S-27S.
2005: Serengulam V Govindan; Gary L Griffiths; Rhona Stein; Philip Andrews; Robert M Sharkey; Hans J Hansen; Ivan D Horak; David M Goldenberg
Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(1):153-9.
2004: Thomas M Cardillo; Habibe Karacay; David M Goldenberg; Dion Yeldell; Chien-Hsing Chang; David E Modrak; Robert M Sharkey; David V Gold
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3552-61.
2004: Gary L Griffiths; Chien-Hsing Chang; William J McBride; Edmund A Rossi; Agatha Sheerin; German R Tejada; Habibe Karacay; Robert M Sharkey; Ivan D Horak; Hans J Hansen; David M Goldenberg
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(1):30-9.
2003: Robert M Sharkey; Arnold Brenner; Jack Burton; George Hajjar; Stephen P Toder; Abass Alavi; Alexander Matthies; Donald E Tsai; Stephen J Schuster; Edward A Stadtmauer; Myron S Czuczman; Dominick Lamonica; Françoise Kraeber-Bodere; Beatrice Mahe; Jean-François Chatal; André Rogatko; George Mardirrosian; David M Goldenberg
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(12):2000-18.
2003: Robert M Sharkey; Edward A Sausville; David M Goldenberg
Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
Cancer research 2003;63(22):8069-71.
2003: Françoise Kraeber-Bodéré; Alain Faivre-Chauvet; Ludovic Ferrer; Jean-Philippe Vuillez; Pierre-Yves Brard; Caroline Rousseau; Isabelle Resche; Anne Devillers; Sophie Laffont; Manuel Bardiès; Ken Chang; Robert M Sharkey; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3973S-81S.
2003: Robert M Sharkey; Habibe Karacay; Heidi Richel; William J McBride; Edmund A Rossi; Ken Chang; Dion Yeldell; Gary L Griffiths; Hans J Hansen; David M Goldenberg
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3897S-913S.
2003: Edmund A Rossi; Robert M Sharkey; William McBride; Habibe Karacay; Li Zeng; Hans J Hansen; David M Goldenberg; Chien-Hsing Chang
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3886S-96S.
2003: David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-François Chatal; Jacques Barbet
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
European journal of nuclear medicine and molecular imaging 2003;30(5):777-80.
2003: Robert M Sharkey; William J McBride; Habibe Karacay; Ken Chang; Gary L Griffiths; Hans J Hansen; David M Goldenberg
A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Cancer research 2003;63(2):354-63.
2003: Gary L Griffiths; Serengulam V Govindan; Robert M Sharkey; Darrell R Fisher; David M Goldenberg
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(1):77-84.
2003: Jeffry A Siegel; Dion Yeldell; David M Goldenberg; Michael G Stabin; Richard B Sparks; Robert M Sharkey; Arnold Brenner; Rosalyn D Blumenthal
Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(1):67-76.
2002: Habibe Karacay; Robert M Sharkey; William J McBride; Gary L Griffiths; Z Qu; Ken Chang; Hans J Hansen; David M Goldenberg
Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Bioconjugate chemistry 2002;13(5):1054-70.
2002: Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-François Chatal; Jacques Barbet; David M Goldenberg
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Molecular cancer therapeutics 2002;1(7):553-63.
2002: George Hajjar; Robert M Sharkey; Jack Burton; Chu-Hui Zhang; Dion Yeldell; Alexander Matthies; Abass Alavi; Michele J Losman; Arnold Brenner; David M Goldenberg
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
Clinical colorectal cancer 2002;2(1):31-42.
2001: David V Gold; Thomas M Cardillo; David M Goldenberg; Robert M Sharkey
Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.
Critical reviews in oncology/hematology 2001;39(1-2):147-54.
2000: Thomas M Behr; Rosalyn D Blumenthal; S Memtsoudis; Robert M Sharkey; Stefan Gratz; Wolfgang Becker; David M Goldenberg
Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4900-7.
2000: Habibe Karacay; William J McBride; Gary L Griffiths; Robert M Sharkey; Jacques Barbet; Hans J Hansen; David M Goldenberg
Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
Bioconjugate chemistry 2000;11(6):842-54.
2000: ME Juweid; George Hajjar; Rhona Stein; Robert M Sharkey; T Herskovic; LC Swayne; S Suleiman; M Pereira; AD Rubin; David M Goldenberg
Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(1):93-103.
1999: Thomas M Behr; Bernhard Wörmann; Martin Gramatzki; Joachim Riggert; Stefan Gratz; Martin Béhé; Frank Griesinger; Robert M Sharkey; H J Kolb; Wolfgang Hiddemann; David M Goldenberg; Wolfgang Becker
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3304s-3314s.
1999: ME Juweid; Edward A Stadtmauer; George Hajjar; Robert M Sharkey; S Suleiman; Selina M Luger; LC Swayne; Abass Alavi; David M Goldenberg
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3292s-3303s.
1999: Thomas M Behr; A L Salib; Torsten Liersch; Martin Béhé; Christa Angerstein; Rosalyn D Blumenthal; Afshin Fayyazi; Robert M Sharkey; B Ringe; Heinz Becker; Bernhard Wörmann; Wolfgang Hiddemann; David M Goldenberg; Wolfgang Becker
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3232s-3242s.
1999: SO Leung; Zhengxing Qu; Hans J Hansen; LB Shih; J Wang; Michele J Losman; David M Goldenberg; Robert M Sharkey
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3106s-3117s.
1999: Thomas M Behr; George Sgouros; M G Stabin; Martin Béhé; Christa Angerstein; Rosalyn D Blumenthal; Christos Apostolidis; Roger Molinet; Robert M Sharkey; Lilli Koch; David M Goldenberg; Wolfgang Becker
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3031s-3043s.
1999: ME Juweid; Chu-Hui Zhang; Rosalyn D Blumenthal; George Hajjar; Robert M Sharkey; David M Goldenberg
Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(10):1609-16.
1999: ME Juweid; George Hajjar; LC Swayne; Robert M Sharkey; S Suleiman; T Herskovic; M Pereira; AD Rubin; David M Goldenberg
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
Cancer 1999;85(8):1828-42.
1998: Serengulam V Govindan; LB Shih; David M Goldenberg; Robert M Sharkey; Habibe Karacay; J E Donnelly; Michele J Losman; Hans J Hansen; Gary L Griffiths
90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Bioconjugate chemistry 1998;9(6):773-82.
1998: Thomas M Behr; S Memtsoudis; Robert M Sharkey; Rosalyn D Blumenthal; RM Dunn; Stefan Gratz; E Wieland; Klaus Nebendahl; Heinz Schmidberger; David M Goldenberg; Wolfgang Becker
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
International journal of cancer. Journal international du cancer 1998;77(5):787-95.
1998: Rosalyn D Blumenthal; RM Alisauskas; W Lew; Robert M Sharkey; David M Goldenberg
Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
Experimental hematology 1998;26(9):859-68.
1998: Zhengxing Qu; Robert M Sharkey; Hans J Hansen; LB Shih; Serengulam V Govindan; J Shen; David M Goldenberg; SO Leung
Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.
Journal of immunological methods 1998;213(2):131-44.
1998: N Reddy; GL Ong; Thomas M Behr; Robert M Sharkey; David M Goldenberg; M Jules Mattes
Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations.
Cancer immunology, immunotherapy : CII 1998;46(1):25-33.
1998: ME Juweid; Robert M Sharkey; LC Swayne; Gary L Griffiths; R Dunn; David M Goldenberg
Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(1):34-42.
1997: ME Juweid; Chu-Hui Zhang; Rosalyn D Blumenthal; Robert M Sharkey; R Dunn; D Dunlop; David M Goldenberg
Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies.
Cancer 1997;80(12 Suppl):2749-53.
1997: RM Dunn; ME Juweid; Robert M Sharkey; Thomas M Behr; David M Goldenberg
Can occult metastases be treated by radioimmunotherapy?
Cancer 1997;80(12 Suppl):2656-9.
1997: Rosalyn D Blumenthal; RM Alisauskas; ME Juweid; Robert M Sharkey; David M Goldenberg
Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?
Cancer 1997;80(12 Suppl):2624-35.
1997: Thomas M Behr; Robert M Sharkey; George Sgouros; Rosalyn D Blumenthal; RM Dunn; Katherine S Kolbert; Gary L Griffiths; Jeffry A Siegel; W S Becker; David M Goldenberg
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Cancer 1997;80(12 Suppl):2591-610.
1997: ME Juweid; LC Swayne; Robert M Sharkey; R Dunn; AD Rubin; T Herskovic; David M Goldenberg
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Gynecologic oncology 1997;67(3):259-71.
1997: ME Juweid; Robert M Sharkey; LC Swayne; David M Goldenberg
Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
Surgery 1997;122(6):1156-65.
1997: Robert M Sharkey; Rosalyn D Blumenthal; Thomas M Behr; G Y Wong; L Haywood; D Forman; Gary L Griffiths; David M Goldenberg
Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.
International journal of cancer. Journal international du cancer 1997;72(3):477-85.
1997: Rosalyn D Blumenthal; Robert M Sharkey; L Haywood; T Behr; David M Goldenberg
Application of cytokine intervention for improved radio-antibody dose delivery.
International journal of cancer. Journal international du cancer 1997;72(1):166-73.
1997: Robert M Sharkey; Habibe Karacay; Gary L Griffiths; Thomas M Behr; Rosalyn D Blumenthal; M Jules Mattes; Hans J Hansen; David M Goldenberg
Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Bioconjugate chemistry 1997;8(4):595-604.
1997: Habibe Karacay; Robert M Sharkey; Serengulam V Govindan; William J McBride; David M Goldenberg; Hans J Hansen; Gary L Griffiths
Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Bioconjugate chemistry 1997;8(4):585-94.
1997: Thomas M Behr; Robert M Sharkey; ME Juweid; RM Dunn; R C Vagg; Zhiliang Ying; Chu-Hui Zhang; LC Swayne; Y Vardi; Jeffry A Siegel; David M Goldenberg
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(6):858-70.
1997: M Jules Mattes; LB Shih; Serengulam V Govindan; Robert M Sharkey; GL Ong; H Xuan; David M Goldenberg
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
International journal of cancer. Journal international du cancer 1997;71(3):429-35.
1997: Robert M Sharkey; Thomas M Behr; M Jules Mattes; Rhona Stein; Gary L Griffiths; LB Shih; Hans J Hansen; Rosalyn D Blumenthal; RM Dunn; ME Juweid; David M Goldenberg
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Cancer immunology, immunotherapy : CII 1997;44(3):179-88.
1997: David M Goldenberg; ME Juweid; RM Dunn; Robert M Sharkey
Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
Journal of nuclear medicine technology 1997;25(1):18-23; quiz 34.
1997: Thomas M Behr; Robert M Sharkey; ME Juweid; RM Dunn; Zhiliang Ying; Chu-Hui Zhang; Jeffry A Siegel; David M Goldenberg
Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(3):409-18.
1997: ME Juweid; RM Dunn; Robert M Sharkey; AD Rubin; Hans J Hansen; David M Goldenberg
99Tcm-LL1: a potential new bone marrow imaging agent.
Nuclear medicine communications 1997;18(2):142-8.
1997: ME Juweid; Robert M Sharkey; Abass Alavi; LC Swayne; T Herskovic; D Hanley; AD Rubin; M Pereira; David M Goldenberg
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(2):257-60.
1997: RM Alisauskas; David M Goldenberg; Robert M Sharkey; Rosalyn D Blumenthal
Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice.
International journal of cancer. Journal international du cancer 1997;70(3):323-9.
1997: Rosalyn D Blumenthal; Robert M Sharkey; R Kashi; K Sides; Rhona Stein; David M Goldenberg
Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(6):367-77.
1996: T M Behr; ME Juweid; Robert M Sharkey; RM Dunn; Zhiliang Ying; W S Becker; Jeffry A Siegel; David M Goldenberg
Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.
Nuclear medicine communications 1996;17(9):767-80.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; R Dunn; J Siegel; David M Goldenberg
Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(9):1504-10.
1996: Rosalyn D Blumenthal; R Stein; Robert M Sharkey; David M Goldenberg; GL Ong; Kenneth M Klein; M Jules Mattes
Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon.
Cancer research 1996;56(15):3508-15.
1996: ME Juweid; Robert M Sharkey; T M Behr; LC Swayne; R Dunn; Zhiliang Ying; Jeffry A Siegel; Hans J Hansen; David M Goldenberg
Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2.
Cancer 1996;78(1):157-68.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; T Herskovic; M Pereira; AD Rubin; D Hanley; R Dunn; J Siegel; David M Goldenberg
Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(6):905-11.
1996: T M Behr; W S Becker; Robert M Sharkey; ME Juweid; RM Dunn; HJ Bair; F G Wolf; David M Goldenberg
Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(5):829-33.
1996: T M Behr; Robert M Sharkey; M I Juweid; RM Dunn; Zhiliang Ying; Chu-Hui Zhang; Jeffry A Siegel; D V Gold; David M Goldenberg
Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Cancer research 1996;56(8):1805-16.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; AD Rubin; T Herskovic; D Hanley; A Markowitz; R Dunn; J Siegel; T Kamal; David M Goldenberg
Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1209-17.
1995: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; AD Rubin; D Hanley; T Herskovic; A Markowitz; J Siegel; David M Goldenberg
Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Cancer research 1995;55(23 Suppl):5946s-5951s.
1995: Robert M Sharkey; ME Juweid; J Shevitz; T Behr; R Dunn; LC Swayne; G Y Wong; Rosalyn D Blumenthal; Gary L Griffiths; Jeffry A Siegel
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Cancer research 1995;55(23 Suppl):5935s-5945s.
1995: ME Juweid; Robert M Sharkey; A Markowitz; T Behr; LC Swayne; R Dunn; Hans J Hansen; J Shevitz; SO Leung; AD Rubin
Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Cancer research 1995;55(23 Suppl):5899s-5907s.
1995: ME Juweid; Robert M Sharkey; Jeffry A Siegel; T Behr; David M Goldenberg
Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
Cancer research 1995;55(23 Suppl):5827s-5831s.
1995: Rosalyn D Blumenthal; Robert M Sharkey; D Forman; G Wong; J Hess; David M Goldenberg
Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.
Experimental hematology 1995;23(10):1088-97.
1995: T M Behr; Robert M Sharkey; ME Juweid; Rosalyn D Blumenthal; RM Dunn; Gary L Griffiths; HJ Bair; F G Wolf; W S Becker; David M Goldenberg
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
Cancer research 1995;55(17):3825-34.
1995: Rosalyn D Blumenthal; R Kashi; Robert M Sharkey; David M Goldenberg
Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability.
International journal of cancer. Journal international du cancer 1995;61(4):557-66.
1995: David V Gold; R Alisauskas; Robert M Sharkey
Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.
Cancer research 1995;55(5):1105-10.
1994: David M Goldenberg; Robert M Sharkey; S Udem; R Vagg; G M Levine; P Conte; LC Swayne; H J Hansen; D Cunniff; J Anton
Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(6):1028-34.
1994: Robert M Sharkey; David M Goldenberg; R Vagg; D Pawlyk; G Y Wong; Jeffry A Siegel; S Murthy; G M Levine; D Izon; P Gascon
Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
Cancer 1994;73(3 Suppl):864-77.
1994: Rhona Stein; R Blumenthal; Robert M Sharkey; David M Goldenberg
Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Cancer 1994;73(3 Suppl):816-23.
1994: Rosalyn D Blumenthal; Robert M Sharkey; D Forman; G Wong; David M Goldenberg
Cytokine intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF.
Cancer 1994;73(3 Suppl):1083-92.
1994: Rosalyn D Blumenthal; Robert M Sharkey; A M Natale; R Kashi; G Wong; David M Goldenberg
Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
Cancer research 1994;54(1):142-51.
1993: Hans J Hansen; David M Goldenberg; E S Newman; R Grebenau; Robert M Sharkey
Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen.
Cancer 1993;71(11):3478-85.
1993: Robert M Sharkey; David M Goldenberg; S Murthy; H Pinsky; R Vagg; D Pawlyk; Jeffry A Siegel; G Y Wong; P Gascon; D O Izon
Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14.
Cancer 1993;71(6):2082-96.
1993: David M Goldenberg; T J Wlodkowski; Robert M Sharkey; E B Silberstein; Aldo N Serafini; I I Garty; R L Van Heertum; E A Higginbotham-Ford; J A Kotler; N Balasubramanian
Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(1):61-70.
1992: Rosalyn D Blumenthal; Robert M Sharkey; L Haywood; A M Natale; G Y Wong; Jeffry A Siegel; S J Kennel; David M Goldenberg
Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Cancer research 1992;52(21):6036-44.
1992: Rosalyn D Blumenthal; Robert M Sharkey; R Kashi; A M Natale; David M Goldenberg
Physiological factors influencing radioantibody uptake: a study of four human colonic carcinomas.
International journal of cancer. Journal international du cancer 1992;51(6):935-41.
1992: Otto Boerman; Robert M Sharkey; Rosalyn D Blumenthal; R L Aninipot; David M Goldenberg
The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors.
International journal of cancer. Journal international du cancer 1992;51(3):470-5.
1992: Robert M Sharkey; Otto Boerman; A Natale; D Pawlyk; Marc Monestier; M J Losman; David M Goldenberg
Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor-bearing nude mice.
International journal of cancer. Journal international du cancer 1992;51(2):266-73.
1992: S Murthy; Robert M Sharkey; David M Goldenberg; R E Lee; C M Pinsky; Hans J Hansen; K Burger; L C Swayne
Lymphoma imaging with a new technetium-99m labelled antibody, LL2.
European journal of nuclear medicine 1992;19(6):394-401.
1992: I Fand; Robert M Sharkey; J P Grundy; David M Goldenberg
Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(1):87-99.
1992: R Stein; Robert M Sharkey; David M Goldenberg
Haematological effects of radioimmunotherapy in cancer patients.
British journal of haematology 1992;80(1):69-76.
1992: Otto Boerman; Robert M Sharkey; G Y Wong; Rosalyn D Blumenthal; R L Aninipot; David M Goldenberg
Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor.
Cancer immunology, immunotherapy : CII 1992;35(2):127-34.
1991: LB Shih; David M Goldenberg; H Xuan; H Lu; Robert M Sharkey; T C Hall
Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier.
Cancer research 1991;51(16):4192-8.
1991: Robert M Sharkey; A Natale; David M Goldenberg; M Jules Mattes
Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice.
Cancer research 1991;51(12):3102-7.
1991: Robert M Sharkey; K S Weadock; A Natale; L Haywood; R Aninipot; Rosalyn D Blumenthal; David M Goldenberg
Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice.
Journal of the National Cancer Institute 1991;83(9):627-32.
1991: M J Losman; Hans J Hansen; Robert M Sharkey; David M Goldenberg; Marc Monestier
Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3421-5.
1991: David M Goldenberg; J A Horowitz; Robert M Sharkey; T C Hall; S Murthy; H Goldenberg; R E Lee; R Stein; Jeffry A Siegel; D O Izon
Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):548-64.
1991: R Stein; Z F Wang; Robert M Sharkey; Kenneth M Klein; David M Goldenberg
A new murine monoclonal antibody against human hepatoma.
Hybridoma 1991;10(2):255-67.
1991: GL Ong; David Ettenson; Robert M Sharkey; A Marks; R Baumal; David M Goldenberg; M Jules Mattes
Galactose-conjugated antibodies in cancer therapy: properties and principles of action.
Cancer research 1991;51(6):1619-26.
1991: Rosalyn D Blumenthal; R Kashi; R Stephens; Robert M Sharkey; David M Goldenberg
Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p.
Cancer immunology, immunotherapy : CII 1991;32(5):303-10.
1991: Rosalyn D Blumenthal; Robert M Sharkey; R Kashi; David M Goldenberg
Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments.
Selective cancer therapeutics 1991;7(1):9-16.
1991: Rosalyn D Blumenthal; I Fand; Robert M Sharkey; Otto Boerman; R Kashi; David M Goldenberg
The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.
Cancer immunology, immunotherapy : CII 1991;33(6):351-8.
1991: C Motta-Hennessy; Robert M Sharkey; David M Goldenberg
Labeling of monoclonal antibody conjugates with 90Y.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1991;42(5):421-6.
1990: LB Shih; H Xuan; Robert M Sharkey; David M Goldenberg
A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model.
International journal of cancer. Journal international du cancer 1990;46(6):1101-6.
1990: David M Goldenberg; Robert M Sharkey; H Goldenberg; T C Hall; S Murthy; D O Izon; P Gascon; L C Swayne
Monoclonal antibody therapy of cancer.
New Jersey medicine : the journal of the Medical Society of New Jersey 1990;87(11 Spec No):913-8.
1990: C Motta-Hennessy; Robert M Sharkey; David M Goldenberg
Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(9):1510-9.
1990: Robert M Sharkey; David M Goldenberg; H Goldenberg; R E Lee; C Ballance; D Pawlyk; D Varga; Hans J Hansen
Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans.
Cancer research 1990;50(9):2823-31.
1990: Robert M Sharkey; C Motta-Hennessy; D Pawlyk; Jeffry A Siegel; David M Goldenberg
Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
Cancer research 1990;50(8):2330-6.
1990: K S Weadock; Robert M Sharkey; D C Varga; David M Goldenberg
Evaluation of a remote radioiodination system for radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(4):508-11.
1990: R Stein; S Chen; Robert M Sharkey; David M Goldenberg
Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting.
Cancer research 1990;50(4):1330-6.
1990: Rosalyn D Blumenthal; Robert M Sharkey; L M Quinn; David M Goldenberg
Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy.
Cancer research 1990;50(3 Suppl):1003s-1007s.
1990: Robert M Sharkey; Rosalyn D Blumenthal; Hans J Hansen; David M Goldenberg
Biological considerations for radioimmunotherapy.
Cancer research 1990;50(3 Suppl):964s-969s.
1990: David M Goldenberg; H Goldenberg; Robert M Sharkey; E Higginbotham-Ford; R E Lee; L C Swayne; K A Burger; D Tsai; J A Horowitz; T C Hall
Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc.
Cancer research 1990;50(3 Suppl):909s-921s.
1990: I Fand; Robert M Sharkey; David M Goldenberg
Use of whole-body autoradiography in cancer targeting with radiolabeled antibodies.
Cancer research 1990;50(3 Suppl):885s-891s.
1990: Robert M Sharkey; David V Gold; R Aninipot; R Vagg; C Ballance; E S Newman; F Ostella; Hans J Hansen; David M Goldenberg
Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.
Cancer research 1990;50(3 Suppl):828s-834s.
1990: Hans J Hansen; A L Jones; Robert M Sharkey; R Grebenau; N Blazejewski; A Kunz; M J Buckley; E S Newman; F Ostella; David M Goldenberg
Preclinical evaluation of an "instant" 99mTc-labeling kit for antibody imaging.
Cancer research 1990;50(3 Suppl):794s-798s.
1990: M J Losman; R L DeJager; Marc Monestier; Robert M Sharkey; David M Goldenberg
Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies.
Cancer research 1990;50(3 Suppl):1055s-1058s.
1990: Jeffry A Siegel; D A Pawlyk; R E Lee; N L Sasso; J A Horowitz; Robert M Sharkey; David M Goldenberg
Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Cancer research 1990;50(3 Suppl):1039s-1042s.
1990: R Stein; Robert M Sharkey; David M Goldenberg
Monoclonal antibody targeting of human non-small cell carcinoma of the lung.
Cancer research 1990;50(3 Suppl):866s-868s.
1990: Z F Wang; R Stein; Robert M Sharkey; David M Goldenberg
Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model.
Cancer research 1990;50(3 Suppl):869s-872s.
1989: Rosalyn D Blumenthal; Robert M Sharkey; R Kashi; A M Natale; David M Goldenberg
Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft.
International journal of cancer. Journal international du cancer 1989;44(6):1041-7.
1989: David M Goldenberg; H Goldenberg; Robert M Sharkey; R E Lee; E Higgenbotham-Ford; J A Horowitz; T C Hall; C M Pinsky; Hans J Hansen
Imaging of colorectal carcinoma with radiolabeled antibodies.
Seminars in nuclear medicine 1989;19(4):262-81.
1989: Rosalyn D Blumenthal; Robert M Sharkey; R Kashi; David M Goldenberg
Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model.
International journal of cancer. Journal international du cancer 1989;44(2):292-300.
1989: Rosalyn D Blumenthal; Robert M Sharkey; D Snyder; David M Goldenberg
Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy.
Journal of the National Cancer Institute 1989;81(3):194-9.
1989: Jeffry A Siegel; R E Lee; D A Pawlyk; J A Horowitz; Robert M Sharkey; David M Goldenberg
Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(6):553-9.
1988: Rosalyn D Blumenthal; Robert M Sharkey; D J Snyder; Hans J Hansen; David M Goldenberg
Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1.
Cancer research 1988;48(19):5403-6.
1988: LB Shih; Robert M Sharkey; F J Primus; David M Goldenberg
Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier.
International journal of cancer. Journal international du cancer 1988;41(6):832-9.
1988: Robert M Sharkey; F A Kaltovich; LB Shih; I Fand; G Govelitz; David M Goldenberg
Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Cancer research 1988;48(11):3270-5.
1988: Robert M Sharkey; J Mabus; David M Goldenberg
Factors influencing anti-antibody enhancement of tumor targeting with antibodies in hamsters with human colonic tumor xenografts.
Cancer research 1988;48(8):2005-9.
1988: Robert M Sharkey; F J Primus; D Shochat; David M Goldenberg
Comparison of tumor targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumor-hamster host model.
Cancer research 1988;48(7):1823-8.
1987: Robert M Sharkey; M J Pykett; Jeffry A Siegel; E A Alger; F J Primus; David M Goldenberg
Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
Cancer research 1987;47(21):5672-7.
1987: David M Goldenberg; Robert M Sharkey; E Ford
Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987;28(10):1604-10.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.